Product logins

Find logins to all Clarivate products below.


Gastrointestinal Stromal Tumor – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key GIST patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact DRG.support@clarivate.com.

Related Market Assessment Reports

Report
Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
Doublet or triplet chemotherapy, alone or in combination with angiogenesis inhibitors, remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS or BRAF mutations…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Non-Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The multibillion-dollar NSCLC therapy market is highly dynamic, with more than 40 targeted drugs approved, but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…